Boston Scientific Corporation
Clinical trials sponsored by Boston Scientific Corporation, explained in plain language.
A global medical device company specializing in minimally invasive interventions.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gel shield could spare prostate cancer patients from radiation damage Results expected Sep 2026 (estimated)
- Double whammy for AFib: single procedure aims to fix rhythm and prevent strokes Results expected Oct 2026 (estimated)
- New device targets recurrent brain tumors in early trial Results expected Oct 2026 (estimated)
- New hope for weight regain after gastric bypass: TORe procedure tested Results expected Nov 2026 (estimated)
- New registry aims to perfect heart ablation workflow Results expected Feb 2027 (estimated)
-
New hope for stroke prevention: device offers alternative to blood thinners for heart patients
Disease control Stopped earlyThis study tested the WATCHMAN device, a small implant that closes off a part of the heart where clots often form, in 481 people with atrial fibrillation who cannot take blood thinners. The goal was to see if the device is safe and effective at reducing stroke risk. Participants …
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for weight loss after GLP-1 failure: Stomach-Sewing procedure tested
Disease control Stopped earlyThis study looked at whether a procedure called endoscopic sleeve gastroplasty (ESG) could help people with obesity who stopped taking GLP-1 weight loss drugs because of side effects or poor results. Researchers compared weight loss and safety in 18 adults who either had ESG plus…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Varicose vein treatment showdown: foam vs. heat
Symptom relief Stopped earlyThis study compared two treatments for varicose veins: Varithena (a foam) and Endothermal Ablation (using heat). It included 43 adults with a faulty great saphenous vein. The goal was to see which treatment better reduced symptoms like heaviness and pain over 3 months.
Phase 4 • Sponsor: Boston Scientific Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
5-Year check: does this stomach procedure keep weight off?
Knowledge-focused Stopped earlyThis study looks at people who had an endoscopic sleeve gastroplasty (ESG) at least 5 years ago to see if they kept the weight off. Researchers will measure total body weight loss at the 5-year mark. The goal is to understand the long-term success of this weight-loss procedure.
Sponsor: Boston Scientific Corporation • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC